Equillium to Present at the BTIG Virtual Biotechnology Conference

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, announced its participation in the BTIG Virtual Biotechnology Conference on August 9 & 10, 2021. CEO Bruce Steel and Dr. Dolca Thomas, EVP of R&D and CMO, will present a clinical overview and engage in a Fireside Chat with analyst Justin Zelin. The event is set for August 10, 2021, at 12 PM ET via a virtual webcast. Equillium is focused on developing itolizumab to address severe autoimmune and inflammatory disorders, including aGVHD, lupus, and asthma.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021.

Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas, M.D., Equillium’s executive vice president of research and development and chief medical officer, will provide a high-level overview of the Company’s clinical focus before engaging in a Fireside Chat with BTIG equity research analyst Justin Zelin.

Date:				Tuesday, August 10, 2021
Time:				12:00 PM Eastern Time | 9:00 AM Pacific Time
Location:				Virtual Webcast

BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005312/en/

FAQ

When is Equillium presenting at the BTIG Virtual Biotechnology Conference?

Equillium will present at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 12 PM Eastern Time.

Who will represent Equillium at the BTIG Conference?

CEO Bruce Steel and Dr. Dolca Thomas, EVP of R&D and CMO, will represent Equillium at the BTIG Conference.

What is the focus of Equillium's presentation at the conference?

Equillium's presentation will provide a high-level overview of its clinical focus and the development of itolizumab.

What diseases is Equillium's itolizumab targeting?

Itolizumab is being developed to treat severe autoimmune and inflammatory disorders such as aGVHD, lupus, and uncontrolled asthma.

How can I listen to Equillium's presentation at the BTIG Conference?

To listen to the live event, please contact your BTIG representative for access.